commercial smallpox vaccines in relation to that of the U.S. Reference by the CAM and RS test methods.
MATERIALS AND METHODS
Types of vaccine. Liquid and dried smallpox vaccines derived from either calf lymph or the CAM of embryonated chicken eggs (produced by U.S. licensed manufacturers, the International Reference Preparation of Smallpox Vaccine, and the U.S. Reference Smallpox Vaccine, Lot 2) were assayed.
Dilution of vaccines. The U.S. Reference used in the RS test was reconstituted with 3 ml of a 50% glycerolwater diluent, and subsequent dilutions were prepared in buffered saline (pH 7.0), following the dilution scheme described in the amended U.S. Minimum Requirements: Smallpox Vaccine (National Institutes of Health, 1965) . For the CAM test, dilutions of the reference vaccine that were reconstituted, as previously mentioned, were prepared in Beef Heart Infusion broth (pH 7.4).
The International Reference Preparation of Smallpox Vaccine was reconstituted and diluted with Mcllvaine buffer in accordance with directions accompanying the vaccine.
We reconstituted dried commercial vaccines according to the directions provided by the manufacturer, and subsequent dilutions were prepared in Beef Heart Infusion broth. Liquid vaccines were diluted in a similar manner.
CAM assay. The dropped CAM of each 12-day-old Table 2 . The mean value obtained for the International Reference by the CAM method is within the limits indicated above. Also, the potency of this reference was satisfactory by the RS test.
Comparison of the potency of commercial smallpox vaccines in relation to the U.S. Reference Smallpox Vaccine. The potency values obtained by the CAM and RS test for the vaccines are given in Table 3 .
We observed that 89% of the potency values agreed, i.e., the potency ratios were not less than 0.7 for the RS test, and the titers were 1081 PFU/ml i 0.5 log for the CAM test.
We considered the CAM test valid if the titer of the reference vaccine was within the limits presented in Table 1 . Similarly, we regarded the test vaccine as satisfactory if its titer was equal to or greater than the low titer given in this table.
A comparison of the potency distribution of the vaccines (Table 4) showed that the liquid vaccines meet the accepted 0.7 RS potency ratio and the acceptable CAM value suggested in Table 1 . with only one exception. But in the case of dried vaccines of the lots which met the RS potency requirements, only 74% of the lots were able to meet a minimal titer of 107 .6 PFU/ml by the CAM test.
In an effort to determine a RS potency ratio which would be "equivalent" to the proposed CAM potency value, we re-evaluated the data. The potency ratios of the vaccine lots were then distributed into two new groups, i.e., 0.8 and 0.9 potency ratios (Table 4) . 
.
The data from our study showed that the CAM test method was applicable to the estimation of the potency of unknown lots of commercial smallpox vaccines if the titration was performed in comparison with that of the U.S. Reference Smallpox Vaccine.
Examination of 27 commercial dried smallpox vaccine lots by the CAM test demonstrated that 26% of the lots failed to meet the minimal potency value of 107 6 PFU/ml. However, of the 44 liquid vaccine lots tested, only 2% failed to meet the proposed CAM potency. All of the dried and liquid vaccine lots met the present RS test requirement.
One factor that may be associated with the presence of a larger number of lower titers for dried vaccines (< 107 6 PFU/ml) than for liquid vaccines is a change in viral activity during the drying process which may reduce infectivity for the chorioallantoic membrane.
Another factor which may account for the difference in viral activity is that the RS test measures skin reactivity, but the CAM test is an estimation of the number of infective viral particles.
Because many of the dried vaccines did not meet the minimum proposed CAM potency value, the RS potency ratios of the dried vaccines were re-evaluated to determine what potency value obtained by each of the two test methods would be equivalent.
We observed that there was no significant difference between the accepted 0.7 RS potency ratio and a proposed 0.8 level for dried vaccines, since only one lot had a RS potency ratio of less than 0.8 during the testing period.
However, at the 0.9 level, four vaccine lots failed the RS test and, in addition, did not meet the proposed CAM value. Furthermore, three vaccine lots which had a RS potency ratio of 0.9, failed to meet the proposed CAM value. Conversely, three other lots which met the proposed CAM value did not meet the 0.9 RS potency ratio. Perhaps these few discrepancies could be resolved by replicate testing of vaccine lots instead of single tests.
Should these findings continue to be observed in subsequent testing, it may be necessary to raise the RS potency ratio for dried vaccines to 0.9 for these vaccines to be equivalent to the potency requirements, when measured by the CAM procedure.
Our correlation of the RS test at the 0.9 level with the proposed CAM value should also satisfy the WHO requirement for correlation of the two test methods (13) .
It is apparent from our data that the CAM test method has application in the control testing of U.S. licensed smallpox vaccines, provided it is used within the limits discussed.
